The Save the Children Immunisation Accelerator has opened a second round of applications, inviting organisations in Nigeria and Ethiopia to submit proposals for innovations that tackle entrenched ...

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest intraday gain in nearly two years and ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

David Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...